JPS59184132A - 百日ぜきワクチンの製造方法 - Google Patents
百日ぜきワクチンの製造方法Info
- Publication number
- JPS59184132A JPS59184132A JP58058548A JP5854883A JPS59184132A JP S59184132 A JPS59184132 A JP S59184132A JP 58058548 A JP58058548 A JP 58058548A JP 5854883 A JP5854883 A JP 5854883A JP S59184132 A JPS59184132 A JP S59184132A
- Authority
- JP
- Japan
- Prior art keywords
- culture
- fraction
- cyclodextrin
- pertussis
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940066827 pertussis vaccine Drugs 0.000 title claims abstract description 17
- 238000004519 manufacturing process Methods 0.000 title claims description 27
- 238000000034 method Methods 0.000 claims abstract description 26
- 241000588832 Bordetella pertussis Species 0.000 claims abstract description 25
- 238000005273 aeration Methods 0.000 claims abstract description 24
- 230000012010 growth Effects 0.000 claims abstract description 22
- 230000001580 bacterial effect Effects 0.000 claims abstract description 19
- 238000013019 agitation Methods 0.000 claims abstract description 18
- 150000001413 amino acids Chemical class 0.000 claims abstract description 17
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 16
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 10
- 208000015181 infectious disease Diseases 0.000 claims abstract description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 8
- 239000001301 oxygen Substances 0.000 claims abstract description 8
- 101710194807 Protective antigen Proteins 0.000 claims abstract description 6
- 239000004471 Glycine Substances 0.000 claims abstract description 5
- 230000003698 anagen phase Effects 0.000 claims abstract description 5
- 239000001963 growth medium Substances 0.000 claims abstract description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 4
- 229930182817 methionine Natural products 0.000 claims abstract description 4
- 239000002609 medium Substances 0.000 claims description 40
- 238000011282 treatment Methods 0.000 claims description 21
- 235000001014 amino acid Nutrition 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 14
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 7
- 230000003254 anti-foaming effect Effects 0.000 claims description 7
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 7
- 239000002518 antifoaming agent Substances 0.000 claims description 6
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 6
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 5
- -1 inleucine Chemical compound 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 3
- 108010024636 Glutathione Proteins 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 3
- 229960003180 glutathione Drugs 0.000 claims description 3
- 230000002458 infectious effect Effects 0.000 claims description 3
- 235000005772 leucine Nutrition 0.000 claims description 3
- 235000006109 methionine Nutrition 0.000 claims description 3
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 claims description 3
- 235000013923 monosodium glutamate Nutrition 0.000 claims description 3
- 239000004223 monosodium glutamate Substances 0.000 claims description 3
- 235000004400 serine Nutrition 0.000 claims description 3
- 239000004474 valine Substances 0.000 claims description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims 1
- 239000001116 FEMA 4028 Substances 0.000 claims 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims 1
- 229960004853 betadex Drugs 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 abstract description 17
- 201000005702 Pertussis Diseases 0.000 abstract description 11
- 206010043376 Tetanus Diseases 0.000 abstract description 4
- 230000005526 G1 to G0 transition Effects 0.000 abstract description 3
- 238000009630 liquid culture Methods 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 description 25
- 239000000243 solution Substances 0.000 description 23
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 22
- 238000003756 stirring Methods 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 13
- 238000001784 detoxification Methods 0.000 description 11
- 239000002244 precipitate Substances 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000012258 culturing Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000000502 dialysis Methods 0.000 description 6
- 230000003068 static effect Effects 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 5
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 5
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 5
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 5
- 235000011130 ammonium sulphate Nutrition 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 206010013023 diphtheria Diseases 0.000 description 3
- 229960003983 diphtheria toxoid Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229960000814 tetanus toxoid Drugs 0.000 description 3
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 3
- 229940033663 thimerosal Drugs 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 2
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940001442 combination vaccine Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000011146 sterile filtration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 101000757109 Canis lupus familiaris Aminopeptidase N Proteins 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 101000597193 Homo sapiens Telethonin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241001510071 Pyrrhocoridae Species 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 102100035155 Telethonin Human genes 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 210000003918 fraction a Anatomy 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000007888 toxin activity Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58058548A JPS59184132A (ja) | 1983-04-02 | 1983-04-02 | 百日ぜきワクチンの製造方法 |
| CA000450495A CA1213234A (en) | 1983-03-30 | 1984-03-26 | Method for the production of ha fraction containing protective antigens of bordetella pertussis and pertussis vaccine |
| EP84103504A EP0121249B1 (en) | 1983-03-30 | 1984-03-29 | Method for the production of ha fraction containing protective antigens of bordetella pertussis and pertussis vaccine |
| KR1019840001645A KR900007658B1 (ko) | 1983-03-30 | 1984-03-29 | 백일해균 예방항원을 함유하는 ha 유분(留分)과 백일해 왁진의 제조방법 |
| DE8484103504T DE3484778D1 (de) | 1983-03-30 | 1984-03-29 | Verfahren zur herstellung der bordetella-pertussis-schutzantigene enthaltenden ha fraktion und keuchhustenvakzin. |
| ES531112A ES8505818A1 (es) | 1983-03-30 | 1984-03-29 | Un metodo para la produccion de una fraccion ha que contiene antigenos protectores de bordetella pertussis |
| AU26230/84A AU564634B2 (en) | 1983-03-30 | 1984-03-29 | Method for production of ha fraction containing protective antigens |
| AT84103504T ATE65028T1 (de) | 1983-03-30 | 1984-03-29 | Verfahren zur herstellung der bordetellapertussis-schutzantigene enthaltenden ha fraktion und keuchhustenvakzin. |
| US06/874,670 US4687738A (en) | 1983-03-30 | 1986-06-16 | Method for the production of HA fraction containing protective antigens of Bordetella pertussis and pertussis vaccine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58058548A JPS59184132A (ja) | 1983-04-02 | 1983-04-02 | 百日ぜきワクチンの製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59184132A true JPS59184132A (ja) | 1984-10-19 |
| JPS64931B2 JPS64931B2 (en, 2012) | 1989-01-10 |
Family
ID=13087507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58058548A Granted JPS59184132A (ja) | 1983-03-30 | 1983-04-02 | 百日ぜきワクチンの製造方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS59184132A (en, 2012) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61271986A (ja) * | 1985-05-27 | 1986-12-02 | Agency Of Ind Science & Technol | リンパ系細胞用培地 |
| JP5207380B2 (ja) * | 2006-03-27 | 2013-06-12 | 北里第一三共ワクチン株式会社 | 長期保存においても毒性復帰がおこらない特徴を持つ全菌体細菌ワクチンならびにその用途 |
| JP2018007676A (ja) * | 2012-02-01 | 2018-01-18 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 発酵方法 |
-
1983
- 1983-04-02 JP JP58058548A patent/JPS59184132A/ja active Granted
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61271986A (ja) * | 1985-05-27 | 1986-12-02 | Agency Of Ind Science & Technol | リンパ系細胞用培地 |
| JP5207380B2 (ja) * | 2006-03-27 | 2013-06-12 | 北里第一三共ワクチン株式会社 | 長期保存においても毒性復帰がおこらない特徴を持つ全菌体細菌ワクチンならびにその用途 |
| JP2018007676A (ja) * | 2012-02-01 | 2018-01-18 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 発酵方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS64931B2 (en, 2012) | 1989-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4687738A (en) | Method for the production of HA fraction containing protective antigens of Bordetella pertussis and pertussis vaccine | |
| KR840001512B1 (ko) | 백일해 톡소이드의 제조방법 | |
| JPS60500597A (ja) | 細菌培養によるヒアルロン酸 | |
| CN102653565A (zh) | 一种从荚膜细菌发酵液纯化荚膜多糖的方法 | |
| CN113025532B (zh) | 一种脑膜炎球菌培养基及其配制方法及培养方法 | |
| JP2011201913A (ja) | Ｉｐｖ−ｄｐｔワクチン | |
| JPS59184132A (ja) | 百日ぜきワクチンの製造方法 | |
| NO159394B (no) | Fremgangsmaate for fremstilling av immunogene kapselformede polyosider fra kapselbakterier. | |
| EP0077646A2 (en) | Method of culturing microbes belonging to the genus Bordetella and culture medium | |
| CA1117866A (en) | Haemophilus influenzae vaccine | |
| JPS59181222A (ja) | 百日ぜき菌の感染防御抗原ｈａ画分の製造方法 | |
| JP2593147B2 (ja) | 感染防御抗原産生菌用培地組成物 | |
| CN111588842A (zh) | 一种多价肺炎球菌多糖蛋白结合疫苗的制备方法 | |
| CN105199998B (zh) | Hib综合培养基、b型流感嗜血杆菌结合疫苗及其制备方法 | |
| CN119955690B (zh) | 一种生产外膜囊泡的化学限定培养基及其用途 | |
| RU2089215C1 (ru) | Способ получения менингококкового серогруппы в липоолигосахарида | |
| KR810001317B1 (ko) | 혼합백신의 제조방법 | |
| JPS5867188A (ja) | 生物学的活性物質の製法 | |
| JPS59187778A (ja) | 微生物を培養するための培地 | |
| JP4162308B2 (ja) | ボルデテラ属細菌用培地組成物及び培養方法 | |
| CN115448981A (zh) | 一种吸附破伤风疫苗的制备方法 | |
| Philipson | Recovery of a cytopathogenic agent from patients with non-diphtheritic croup, and from day-nursery children: II. Physico-chemical and growth characteristics | |
| CN112538120A (zh) | b型流感嗜血杆菌荚膜多糖制备方法 | |
| BR102019021510A2 (pt) | Processo de produção, recuperação e purificação de polissacarídeo capsular poliribosil-ribitol-fosfato (prp) e uso do mesmo | |
| CN106237320A (zh) | 一种a群c群脑膜炎球菌多糖结合疫苗的制备方法 |